A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bezafibrate/obeticholic acid (Primary) ; Bezafibrate; Obeticholic acid
Indications Primary biliary cirrhosis
Focus Therapeutic Use
Sponsors Intercept Pharmaceuticals

Most Recent Events

23 Jan 2025 Planned End Date changed from 1 Feb 2025 to 1 Oct 2025.
23 Jan 2025 Planned primary completion date changed from 1 Nov 2024 to 1 Oct 2025.
03 Jul 2024 Planned End Date changed from 1 Aug 2024 to 1 Feb 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight